Sera Prognostics Inc - Ordinary Shares Class A Stock News

The PRIME study, one of the largest studies on preterm birth, has been accepted for publication by a medical journal following abstract presentation earlier this year SALT LAKE CITY , Nov. 24, 2025 /PRNewswire/ -- Sera Prognostics, Inc. , The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors an...

Sera Prognostics, Inc. ( SERA ) Q3 2025 Earnings Call November 13, 2025 5:00 PM EST Company Participants Jennifer Zibuda - Head of Investor Relations Evguenia Lindgardt - President, CEO & Director Austin Aerts - Chief Financial Officer Conference Call Participants Daniel Brennan - TD Cowen, Research Division Margarate Boeye - William Blair & Company L.L.C., Research Division Presentation Operat...

SALT LAKE CITY , Nov. 13, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the third quarter of 2025 ended September 30, 2025. Third Quarter and Recent Highlights: Meaningful progress on payer i...

SALT LAKE CITY , Oct. 30, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced it will report third quarter fiscal year 2025 financial results on Thursday November 13, 2025, after the close of the market. The Company wil...

SALT LAKE CITY , Oct. 1, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker testing to help deliver information to doctors and patients, today announced the appointment of Tiffany Inglis, MD, FACOG, as Chief Medical Officer. With extensive clinical leadership expertise, ...

SALT LAKE CITY , Aug. 28, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the company will present at the H.C. Wainwright 27th Annual Global Investment Conference on Friday, September 5, 2025 at 7:00 a.m.

Sera Prognostics, Inc. (NASDAQ:SERA ) Q2 2025 Earnings Conference Call August 6, 2025 5:00 PM ET Company Participants Austin Aerts - Chief Financial Officer Evguenia Lindgardt - President, CEO & Director Conference Call Participants Margarate Elizabeth Boeye - William Blair & Company L.L.C., Research Division William Ruby - TD Cowen, Research Division Peter DeNardo - Unidentified Company Operat...

Sera Prognostics (SERA 12.24%), a diagnostic company specializing in pregnancy risk prediction, reported Q2 2025 results on August 6, 2025. The company's headline news was a net loss improvement and continued strategic investment toward commercial rollout, despite revenue remaining extremely modest.